Objective: To estimate the duration of moderate-to-severe menopausal hot flushes and identify potential risk factors for hot flush duration.
Methods: The Penn Ovarian Aging Study cohort was monitored for 13 years. Hot flushes were evaluated at 9-month to 12-month intervals through in-person interviews. The primary outcome was the duration of moderate-to-severe hot flushes estimated by survival analysis (n=259). Potential risk factors included menopausal stage, age, race, reproductive hormone levels, body mass index (BMI), and current smoking. A secondary analysis included women who reported any hot flushes (n=349).
Results: The median duration of moderate-to-severe hot flushes was 10.2 years and was strongly associated with menopausal stage at onset. Hot flushes that started near entry into the menopause transition had a median duration greater than 11.57 years; onset in the early transition stage had a median duration of 7.35 years (95% confidence interval [CI] 4.94-8.89; P<.001); and onset in the late transition to postmenopausal stages had a median duration of 3.84 years (95% CI 1.77-5.52; P<.001). The most common ages at onset of moderate-to-severe hot flushes were 45-49 years (median duration, 8.1 years; 95% CI 5.12-9.28). African American women had a longer duration of hot flushes than white women in adjusted analysis.
Conclusion: The median duration of hot flushes considerably exceeded the timeframe that is generally accepted in clinical practice. The identified risk factors, particularly menopausal stage, race, and BMI, are important to consider in individualizing treatment and evaluating the risk-to-benefit ratio of hormones and other therapies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085137 | PMC |
http://dx.doi.org/10.1097/AOG.0b013e318214f0de | DOI Listing |
Cancers (Basel)
January 2025
Department of Medical Oncology & Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
Background/objectives: This study describes the sequelae, side effects, and toxicities experienced by Canadian breast cancer survivors at a breast cancer survivorship clinic at a tertiary academic cancer centre and identifies potential risk factors which may be associated with increased side effect burden.
Methods: A retrospective chart review was performed of adult patients treated at the Sunnybrook Breast Cancer Survivorship Clinic from 6 July 2022, to 30 September 2023 ( = 435).
Results: Most patients (72.
Cancers (Basel)
January 2025
College of Nursing, University of Illinois Chicago, Chicago, IL 60612, USA.
Background/objectives: Breast cancer survivors undergoing long-term endocrine therapy often experience multiple symptoms, including pain, fatigue, sleep disturbance, hot flashes, anxiety, and depression. This study explored the feasibility and acceptability of integrating acupuncture for symptom management in medically underserved breast cancer survivors.
Methods: This randomized controlled trial was conducted at two clinics serving medically underserved populations.
Eur J Med Res
January 2025
Faculty of Medicine, Menoufia University, Yassin Abdelghaffar Street From Gamal Abdelnaser Street, Shebin Al-Kom, 32511, Menoufia, Egypt.
Background: Postmenopausal women are more likely to experience vasomotor symptoms (VMS), such as heat sensation and sweating. Recent trials have investigated fezolinetant in the treatment of VMS in postmenopausal women. Our study aims to conduct a meta-analysis of these trials in order to estimate fezolinetant's effectiveness and safety in the management of VMS in postmenopausal women.
View Article and Find Full Text PDFIran J Pharm Res
June 2024
Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Context: Breast cancer poses significant challenges due to its high incidence and prevalence, necessitating heightened attention. Understanding how patients prioritize different treatment options based on various attributes can assist healthcare decision-makers in maximizing patient utility. The discrete choice experiment, a conjoint method, facilitates preference elicitation by presenting different attributes and choices.
View Article and Find Full Text PDFJ Menopausal Med
December 2024
Department of Community Medicine, Manipal University College Malaysia, Melaka, Malaysia.
Hormone replacement therapy (HRT) used to treat hot flashes has side effects, such as an increased risk of coronary heart disease and breast cancer. There are ongoing controversies regarding the risk of ovarian cancer associated with HRT. HRT is best avoided in conditions such as liver or gallbladder disease and gastrointestinal disorders.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!